ID KKU-213B AC CVCL_M264 SY KKU-M214; KKUM214; M214; KKU-214; KKU214; Khon Kaen University-M214 DR JCRB; JCRB1556 DR Wikidata; Q54900011 RX PubMed=15884115; RX PubMed=16475706; RX PubMed=18714155; RX PubMed=21871105; RX PubMed=22926522; RX PubMed=25998688; RX PubMed=31077409; RX PubMed=32207095; RX PubMed=35640676; WW Info; ICLAC; -; https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx CC Problematic cell line: Contaminated. Shown to be a KKU-213A derivative (PubMed=32207095 and JCRB web site). CC Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00592. CC Population: Southeast Asian; Thai. CC Doubling time: 22.68 +- 2.20 hours (PubMed=25998688); 24.5 +- 0.2 hours (PubMed=32207095). CC Karyotypic information: Has lost chromosome Y. CC Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Unspecified (from parent cell line). CC Omics: Transcriptomics; Microarray. CC Caution: After JCRB found out that KKU-M156 and KKU-M214 were derived from KKU-M213, these three cell lines were renamed by the lab which established them: KKU-M213 became KKU-213A, KKU-M214 became KKU-M213B and KKU-M156 became KKU-M213C (PubMed=32207095). CC Discontinued: JCRB; JCRB1556; probable. CC Derived from site: In situ; Liver; UBERON=UBERON_0002107. ST Source(s): PubMed=32207095 ST Amelogenin: X ST CSF1PO: 9,13 ST D13S317: 8,12 ST D16S539: 9,11 ST D18S51: 14 ST D19S433: 13,14 ST D21S11: 29 ST D2S1338: 22,23,24 ST D3S1358: 15 ST D5S818: 9 ST D7S820: 11 ST D8S1179: 11,13 ST FGA: 16,19 ST TH01: 7 ST TPOX: 8 ST vWA: 18 DI NCIt; C35417; Intrahepatic cholangiocarcinoma DI NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma DI ORDO; Orphanet_70567; Cholangiocarcinoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) HI CVCL_M261 ! KKU-213A SX Male AG 58Y CA Cancer cell line DT Created: 05-11-13; Last updated: 10-04-25; Version: 20 CH CVCL_C1L6 ! KKU-M214/246 CH CVCL_C1L7 ! KKU-M214/9 CH CVCL_HF58 ! KKU-M214/GEM // RX PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007; PMCID=PMC9472155; RA Isidan, Abdulkadir RA Yenigun, Ali RA Soma, Daiki RA Aksu, Eric RA Lopez, Kevin RA Park, Yujin RA Cross-Najafi, Arthur RA Li, Ping RA Kundu, Debjyoti RA House, Michael G. RA Chakraborty, Sanjukta RA Glaser, Shannon RA Kennedy, Lindsey RA Francis, Heather RA Zhang, Wen-Jun RA Alpini, Gianfranco D. RA Ekser, Burcin RT "Development and characterization of human primary cholangiocarcinoma RT cell lines."; RL Am. J. Pathol. 192:1200-1217(2022). // RX PubMed=25998688; DOI=10.3892/ijo.2015.3019; RA Wattanawongdon, Wareeporn RA Hahnvajanawong, Chariya RA Namwat, Nisana RA Kanchanawat, Sirimas RA Boonmars, Thidarut RA Jearanaikoon, Patcharee RA Leelayuwat, Chanwit RA Techasen, Anchalee RA Seubwai, Wunchana RT "Establishment and characterization of gemcitabine-resistant human RT cholangiocarcinoma cell lines with multidrug resistance and enhanced RT invasiveness."; RL Int. J. Oncol. 47:398-410(2015). // RX PubMed=16475706; RA Panichakul, Tasanee RA Intachote, Pakamas RA Wongkajornsilp, Adisak RA Sripa, Banchob RA Sirisinha, Stitaya RT "Triptolide sensitizes resistant cholangiocarcinoma cells to RT TRAIL-induced apoptosis."; RL Anticancer Res. 26:259-265(2006). // RX PubMed=22926522; DOI=10.1038/onc.2012.382; PMCID=PMC3869796; RA Kunkeaw, Nawapol RA Jeon, Sung Ho RA Lee, Kwanbok RA Johnson, Betty H. RA Tanasanvimon, Suebpong RA Javle, Milind RA Pairojkul, Chawalit RA Chamgramol, Yaovalux RA Wongfieng, Wipaporn RA Gong, Bin RA Leelayuwat, Chanwit RA Lee, Yung Sun RT "Cell death/proliferation roles for nc886, a non-coding RNA, in the RT protein kinase R pathway in cholangiocarcinoma."; RL Oncogene 32:3722-3731(2013). // RX PubMed=18714155; DOI=10.1159/000151541; RA Namwat, Nisana RA Amimanan, Piyawan RA Loilome, Watcharin RA Jearanaikoon, Patcharee RA Sripa, Banchob RA Bhudhisawasdi, Vajarabhongsa RA Tassaneeyakul, Wichittra RT "Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell RT lines."; RL Chemotherapy 54:343-351(2008). // RX PubMed=32207095; DOI=10.1007/s13577-020-00334-w; RA Sripa, Banchob RA Seubwai, Wunchana RA Vaeteewoottacharn, Kulthida RA Sawanyawisuth, Kanlayanee RA Silsirivanit, Atit RA Kaewkong, Worasak RA Muisuk, Kanha RA Dana, Paweena RA Phoomak, Chatchai RA Lert-itthiporn, Worachart RA Luvira, Vor RA Pairojkul, Chawalit RA Teh, Bin Tean RA Wongkham, Sopit RA Okada, Seiji RA Chamgramol, Yaovalux RT "Functional and genetic characterization of three cell lines derived RT from a single tumor of an Opisthorchis viverrini-associated RT cholangiocarcinoma patient."; RL Hum. Cell 33:695-708(2020). // RX PubMed=15884115; DOI=10.3748/wjg.v11.i18.2748; PMCID=PMC4305909; RA Tepsiri, Nisana RA Chaturat, Liengchai RA Sripa, Banchob RA Namwat, Wises RA Wongkham, Sopit RA Bhudhisawasdi, Vajarabhongsa RA Tassaneeyakul, Wichittra RT "Drug sensitivity and drug resistance profiles of human intrahepatic RT cholangiocarcinoma cell lines."; RL World J. Gastroenterol. 11:2748-2753(2005). // RX PubMed=21871105; DOI=10.1186/1476-4598-10-102; PMCID=PMC3173387; RA Obchoei, Sumalee RA Weakley, Sarah M. RA Wongkham, Sopit RA Wongkham, Chaisiri RA Sawanyawisuth, Kanlayanee RA Yao, Qi-Zhi RA Chen, Chang-Yi RT "Cyclophilin A enhances cell proliferation and tumor growth of liver RT fluke-associated cholangiocarcinoma."; RL Mol. Cancer 10:102.1-102.15(2011). // RX PubMed=31077409; DOI=10.1002/hep.30704; RA Sittithumcharee, Gunya RA Suppramote, Orawan RA Vaeteewoottacharn, Kulthida RA Sirisuksakun, Chumphon RA Jamnongsong, Supawan RA Laphanuwat, Phatthamon RA Suntiparpluacha, Monthira RA Matha, Arriya RA Chusorn, Porncheera RA Buraphat, Pongsakorn RA Kakanaporn, Chumpot RA Charngkaew, Komgrid RA Silsirivanit, Atit RA Korphaisarn, Krittiya RA Limsrichamrern, Somchai RA Tripatara, Pinpat RA Pairojkul, Chawalit RA Wongkham, Sopit RA Sampattavanich, Somponnat RA Okada, Seiji RA Jirawatnotai, Siwanon RT "Dependency of cholangiocarcinoma on cyclin D-dependent kinase RT activity."; RL Hepatology 70:1614-1630(2019). //